Equities Analysts Offer Predictions for ACAD FY2027 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at HC Wainwright cut their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Friday, September 25th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will post earnings per share of $1.87 for the year, down from their previous estimate of $1.89. HC Wainwright currently has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.64 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.93 EPS, FY2029 earnings at $3.26 EPS and FY2030 earnings at $3.40 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The business had revenue of $308.00 million during the quarter, compared to the consensus estimate of $296.55 million. During the same period in the prior year, the company posted $0.16 EPS. The firm’s revenue for the quarter was up 16.4% compared to the same quarter last year.

A number of other equities research analysts also recently commented on ACAD. Deutsche Bank Aktiengesellschaft decreased their target price on ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, September 25th. Citigroup reaffirmed a “buy” rating and set a $33.00 price objective (down from $40.00) on shares of ACADIA Pharmaceuticals in a report on Friday, September 25th. TD Cowen reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 24th. Citizens Jmp decreased their price target on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating on the stock in a research note on Friday, September 25th. Finally, UBS Group lifted their price objective on shares of ACADIA Pharmaceuticals from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.76.

ACADIA Pharmaceuticals Stock Down 0.3%

Shares of ACADIA Pharmaceuticals stock opened at $20.15 on Tuesday. The firm has a market cap of $3.47 billion, a price-to-earnings ratio of 9.08 and a beta of 0.86. The business has a 50-day moving average price of $27.21 and a 200-day moving average price of $24.16. ACADIA Pharmaceuticals has a twelve month low of $19.69 and a twelve month high of $30.96.

Institutional Trading of ACADIA Pharmaceuticals

A number of large investors have recently made changes to their positions in ACAD. Cim Investment Management Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 7.3% in the second quarter. Cim Investment Management Inc. now owns 15,273 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 1,034 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in ACADIA Pharmaceuticals in the 2nd quarter worth about $597,000. Integrated Wealth Concepts LLC purchased a new position in shares of ACADIA Pharmaceuticals during the second quarter worth approximately $50,000. Baird Financial Group Inc. bought a new stake in shares of ACADIA Pharmaceuticals during the second quarter valued at approximately $232,000. Finally, Nykredit A S purchased a new stake in shares of ACADIA Pharmaceuticals in the second quarter valued at approximately $38,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 14,292 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $29.22, for a total value of $417,612.24. Following the sale, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,981,934.16. This represents a 17.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. The trade was a 46.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 36,699 shares of company stock valued at $1,019,894. 26.20% of the stock is owned by corporate insiders.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: The U.S. Patent and Trademark Office allowed ACADIA’s patent application covering weight-banded dosing of trofinetide, the active ingredient in Daybue. If issued, the patent could extend U.S. protection for the Rett syndrome treatment through March 2041, helping protect future revenue and limiting generic competition. Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent
• Positive Sentiment: Analyst coverage continues to support ACADIA’s longer-term growth case. HC Wainwright maintained a “Buy” rating and a $33 price target, while forecasts project EPS growth from $1.87 in fiscal 2027 to $3.40 in fiscal 2030. Daybue’s sales growth and European approval could further expand trofinetide’s commercial opportunity. Acadia’s Daybue Patent Allowance Extends U.S. Protection to March 2041
• Neutral Sentiment: HC Wainwright made small reductions to its EPS estimates for fiscal 2027 through 2030—cutting them by $0.02 per share for each year—while retaining its Buy rating and $33 target. The revisions suggest limited near-term concern but do not represent a major change to the firm’s valuation view. What is HC Wainwright’s Estimate for ACAD FY2027 Earnings?
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of ACADIA investors. The announcement provides few details, but shareholder investigations can create legal uncertainty, reputational risk and possible future costs, weighing on investor sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company is headquartered in San Diego, California, and serves patients and healthcare providers primarily in the United States.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.